Physician profile
Eusebio C Kho
NPI 1891801312
$617.18
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.62 · 2020: $33.66 · 2021: $449 · 2022: $92.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $211.36 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $138.77 | 2021-2022 | |
| Glaxosmithkline, LLC. | $97.34 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $61.81 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.58 | 2022 | |
| Shire North American Group INC | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eusebio Kho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.